Ann: Appendix 3B, page-3

First 3 Last

Share
Profile

Follow
squire

4,929 Posts.

02/11/17

10:29

Post #: 28428375
Share

Originally posted by Shady Merv ↑

Hmmmmmmmmmmmmm!

This is for the issue of 9,375,000 shares arising out of the Somers' underwriting - @8c a share too.

So, the big question is: What about the other 6,250,000 shares?

$1.25m shares @8c = 15,625,000 shares

The 17/10 ann said this re the 9,375,000 shares ($750k @8c = 9.375m shares):

'..........a prominent professional and sophisticated shareholder has subscribed for $0.75m of new fully paid ordinary shares in Auris at $0.08 per share via sub-underwriting agreements with Somers and Partners Pty Ltd (Underwriter) in relation to the underwriting of the AUROA Options.'

So, they were done and dusted on or before 17/10 - no worries there except the delay in the App 3B for them (out today).

The 17/10 ann said this about the 6.25m shares:

'The balance of 6,250,000 fully paid ordinary shares at $0.08 per share will be allotted to the Underwriter once cleared funds are received.'

It's pretty simple to work out I think.

1. The money ($500k) for the 6.25m shares @8c either never came in or payment was not cleared.

2. HQ waited and waited for it, expecting cleared funds, and so held back the App3B.

3. Someone (x 1, x 2 x 3 ???) reneged.

4. A prominent professional and sophisticated shareholder paid $750k, so did not renege! Who was it? Will we see a Notice of change in substantial holding?

Now that that's out of the way, let's get some DHEM and assay news out please!

Expand

It's not surprising it's not filled. Would like to have an explanation, particularly after the last annt said the full allocation has been filled.

AUR Price at posting: 6.3¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 7 more messages in this thread...

First 3 Last

Add AUR (ASX) to my watchlist

(20min delay)
Last 0.5¢		Change 0.000(0.00%)		Mkt cap ! $2.383M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	84000	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	445455	2

View Market Depth

No.	Vol.	Price($)
1	84000	0.006
6	2271758	0.005
4	1049480	0.004
5	2805000	0.003
3	2200000	0.002

Price($)	Vol.	No.
0.007	445455	2
0.008	100000	1
0.009	140000	1
0.010	984315	2
0.012	32225	1

Last trade - 16.12pm 07/10/2024 (20 minute delay)

AUR (ASX) Chart

Day chart unavailable

Ann: Appendix 3B, page-3

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Appendix 3B, page-3

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News